TY - JOUR
T1 - Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin's lymphoma patients
AU - Inaoka, Riguel J.
AU - Jungbluth, Achim A.
AU - Gnjatic, Sacha
AU - Ritter, Erika
AU - Hanson, Nicole C.
AU - Frosina, Denise
AU - Tassello, Jodie
AU - Etto, Leina Y.
AU - Bortoluzzo, Adriana B.
AU - Alves, Antonio C.
AU - Colleoni, Gisele W.B.
N1 - Funding Information:
Acknowledgments This work was partially supported by grants from CAPES (RJI) and CNPq (GWBC).
PY - 2012/12
Y1 - 2012/12
N2 - Background Based on their tumor-associated expression pattern, cancer/testis antigens (CTAs) are considered potential targets for cancer immunotherapy. We aim to evaluate the expression of CTAs in non-Hodgkin's lymphoma (NHL) samples and the ability of these patients to elicit spontaneous humoral immune response against CTAs. Methods Expression of MAGE-A family, CT7/MAGEC1, CT10/MAGE-C2, GAGE and NY-ESO-1 was analyzed by immunohistochemistry in a tissue microarray generated from 106 NHL archival cases. The humoral response against 19 CTAs was tested in 97 untreated NHL serum samples using ELISA technique. Results 11.3 % of NHL tumor samples expressed at least 1 CTA. MAGE-A family (6.6 %), GAGE (5.7 %) and NY-ESO-1(4.7 %) were the most frequently expressed antigens. We found no statistically significant correlation between CTA positivity and clinical parameters such as NHL histological subtype, Ann Arbor stage, international prognostic index score, response to treatment and overall survival. Humoral response against at least 1 CTA was observed in 16.5 % of NHL serum samples. However, overall seroreactivity was low, and strong titers ([1:1000) were observed in only two diffuse large B-cell lymphomas patients against CT45. Conclusion Our findings are in agreement with most of published studies in this field to date and suggest an overall low expression of CTAs in NHL patients. However, as many new CTAs have been described recently and some of them are found to be highly expressed in NHL cell lines and tumor samples, further studies exploring the expression of different panels of CTAs are needed to evaluate their role as candidates for immunotherapy in NHL patients.
AB - Background Based on their tumor-associated expression pattern, cancer/testis antigens (CTAs) are considered potential targets for cancer immunotherapy. We aim to evaluate the expression of CTAs in non-Hodgkin's lymphoma (NHL) samples and the ability of these patients to elicit spontaneous humoral immune response against CTAs. Methods Expression of MAGE-A family, CT7/MAGEC1, CT10/MAGE-C2, GAGE and NY-ESO-1 was analyzed by immunohistochemistry in a tissue microarray generated from 106 NHL archival cases. The humoral response against 19 CTAs was tested in 97 untreated NHL serum samples using ELISA technique. Results 11.3 % of NHL tumor samples expressed at least 1 CTA. MAGE-A family (6.6 %), GAGE (5.7 %) and NY-ESO-1(4.7 %) were the most frequently expressed antigens. We found no statistically significant correlation between CTA positivity and clinical parameters such as NHL histological subtype, Ann Arbor stage, international prognostic index score, response to treatment and overall survival. Humoral response against at least 1 CTA was observed in 16.5 % of NHL serum samples. However, overall seroreactivity was low, and strong titers ([1:1000) were observed in only two diffuse large B-cell lymphomas patients against CT45. Conclusion Our findings are in agreement with most of published studies in this field to date and suggest an overall low expression of CTAs in NHL patients. However, as many new CTAs have been described recently and some of them are found to be highly expressed in NHL cell lines and tumor samples, further studies exploring the expression of different panels of CTAs are needed to evaluate their role as candidates for immunotherapy in NHL patients.
KW - Cancer/testis antigens
KW - Humoral response
KW - Non-Hodgkin's lymphoma
UR - http://www.scopus.com/inward/record.url?scp=84870976831&partnerID=8YFLogxK
U2 - 10.1007/s00262-012-1285-6
DO - 10.1007/s00262-012-1285-6
M3 - Review article
C2 - 22638551
AN - SCOPUS:84870976831
SN - 0340-7004
VL - 61
SP - 2207
EP - 2214
JO - Cancer Immunology, Immunotherapy
JF - Cancer Immunology, Immunotherapy
IS - 12
ER -